Shots:
- The approval is based on P-III DAPA-HF trial involves assessing of Forxiga (10mg, qd) + SOC (ACEi or ARB) vs PBO + SOC in 4,744 patients with HFrEF (LVEF ≤ 40%) with/ out T2D
- The study demonstrated 26% reduction in the risk of the composite of CV death or worsening of HF events, including hHF. The safety profile of Forxiga was consistent with the well-established safety profile of the therapy
- Forxiga is the first SGL2 inhibitor, currently being tested for HFpEF in the DELIVER P-III trial with its anticipated data in the H1’21
Click here to read full press release/ article | Ref: AstraZeneca | Image: Market Watch
The post AstraZeneca’s Forxiga (dapagliflozin) Receives NMPA’s Approval for Chronic Heart Failure first appeared on PharmaShots.
